Table 2 Global response according to history of papules, plaques or tumors (PPT).

From: Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma

 

All patients

History of PPT?

No (TCM)

Yes (TRM/TMM)

N

%

N

%

N

%

Global response

      

CR

17

44.7

8

72.7

9

33.3

PR

7

18.4

3

27.3

4

14.8

SD

9

23.7

–

–

9

33.3

PD

5

13.2

–

–

5

18.5

Response

      

CR/PR

24

63.2

11

100.0

13

48.2

SD/PD

14

36.8

–

–

14

51.9

CR rate

      

CR

17

44.7

8

72.7

9

33.3

non-CR

21

55.3

3

27.3

18

66.7

Back to article page